GRANULES Granules India Q3 FY26 results (Oct–Dec 2025) and concall
Granules India delivered a strong Q3 FY26, reporting a 22% YoY revenue growth to INR1,388 crores and a 34% YoY EBITDA increase to INR308 crores, despite a temporary INR248 million loss in its Peptide CDMO business. The company made substantial regulatory progress across its facilities, including a post-warning letter meeting for Gagillapur and multiple GMP certifications/approvals. Granules is strategically focusing on higher complexity generics and anticipates new product launches from its Genome Valley facility and in controlled substances, aiming for continued growth and profitability.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 6.3%, net profit up 24.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 568 | 842 | 768 | 810 | 892 +57% | 895 +6% |
| EBITDA | 103 | 168 | 117 | 144 | 211 +105% | 194 +15% |
| Net profit | 41 | 90 | 94 | 69 | 121 +195% | 112 +24% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
